rocuronium has been researched along with Neuroleptic-Malignant-Syndrome* in 3 studies
3 other study(ies) available for rocuronium and Neuroleptic-Malignant-Syndrome
| Article | Year |
|---|---|
Rocuronium-sugammadex for electroconvulsive therapy management in neuroleptic malignant syndrome: A case report.
Neuroleptics are a group of drugs widely used in the treatment of psychotic symptoms. Among their adverse effects is the ability to trigger a neuroleptic malignant syndrome (NMS). The diagnosis of NMS is determined by exclusion, and its initial therapeutic management should be the withdrawal of neuroleptics, the administration of benzodiazepines, and electroconvulsive therapy (ECT). ECT is an effective treatment in these patients, and in those cases with a poor response to treatment with antipsychotic drugs. A review is presented on the treatment options and anaesthetic implications of ECT used to handle a patient diagnosed with paranoid schizophrenia in the context of NMS. Topics: Androstanols; Anesthetics, Intravenous; Antipsychotic Agents; Clozapine; Electroconvulsive Therapy; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neuroleptic Malignant Syndrome; Neuromuscular Monitoring; Neuromuscular Nondepolarizing Agents; Propofol; Rocuronium; Schizophrenia, Paranoid; Sugammadex | 2017 |
Electroconvulsive therapy using rocuronium and sugammadex in patient with neuroleptic malignant syndrome.
Topics: Androstanols; Bipolar Disorder; Diabetes Insipidus; Electroconvulsive Therapy; Female; gamma-Cyclodextrins; Humans; Lithium Carbonate; Middle Aged; Neuroleptic Malignant Syndrome; Neuromuscular Depolarizing Agents; Rocuronium; Succinylcholine; Sugammadex | 2011 |
[Anesthetic management for electroconvulsive therapy using rocuronium bromide and sugammadex sodium in a patient with suspected malignant syndrome].
A 62-year-old woman was treated for schizophrenia for 40 years. When the symptoms had deteriorated and new medications had to be added, CPK rose and she malignant syndrome was suspected. The electroconvulsive therapy (ECT) was proposed because of no improvement of the symptoms. We employed rocuronium bromide instead of suxamethonium considering malignant syndrome. The maintenance of anesthesia was necessary, because the duration of rocuronium bromide is longer than that of suxamethonium chloride. Anesthesia was induced and maintained using target controlled infusion (TCI) of propofol. After ECT was performed, sugammadex sodium 4 mg . kg-1 was administered at 2 post-tetanic counts (PTC) and the patient could come out the operating room safely and speedy. ECT using rocuronium bromide and sugammadex sodium can be performed safely and speedily, when suxamethonium chloride cannot be used. Topics: Androstanols; Anesthesia, General; Electroconvulsive Therapy; Female; gamma-Cyclodextrins; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Neuromuscular Nondepolarizing Agents; Rocuronium; Sugammadex | 2011 |